SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 122.98 |
| Enterprise Value ($M) | 127.51 |
| Book Value ($M) | 21.54 |
| Book Value / Share | 1.26 |
| Price / Book | 5.71 |
| NCAV ($M) | -9.44 |
| NCAV / Share | -0.55 |
| Price / NCAV | -13.03 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.18 |
| Return on Assets (ROA) | -0.12 |
| Return on Equity (ROE) | -0.64 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 1.03 |
| Current Ratio | 1.34 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 53.99 |
| Assets | 84.96 |
| Liabilities | 63.42 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 56.13 |
| Operating Income | -13.68 |
| Net Income | -14.67 |
| Earnings Per Share Basic And Diluted | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -9.13 |
| Cash from Investing | -15.00 |
| Cash from Financing | 16.99 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G/A | Tang Capital Management Llc | 8.00 | 21.70 | |
| 13G | Wasatch Advisors Inc | 5.40 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 117,908 | 371,772 | 31.72 | |
| 14,777 | 102,567 | 14.41 | |
| 17,518 | 77,763 | 22.53 | |
| 10,968 | 40,790 | 26.89 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| CYCN – Cyclerion Therapeutics, Inc. | CYRX – Cryoport, Inc. |
| DARE – Daré Bioscience, Inc. | DMAC – DiaMedica Therapeutics Inc. |
| DNTH – Dianthus Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io